[1] Vasques F, Cavazza A, Bernal W. Acute liver failure. Curr Opin Crit Care,2022,28(2): 198-207.
[2] 中华医学会感染病学分会肝衰竭与人工肝学组,中华医学会肝病学分会重型肝病与人工肝学组. 肝衰竭诊治指南(2018年版).中华肝脏病杂志, 2019,27(1): 18-26.
[3] Stravitz RT, Fontana RJ, Karvellas C, et al. Future directions in acute liver failure. Hepatology,2023,78(4): 1266-1289.
[4] Rao A, Rule JA, Hameed B, et al. Secular Trends in Severe Idiosyncratic Drug-Induced Liver Injury in North America: An Update From the Acute Liver Failure Study Group Registry. Am J Gastroenterol,2022,117(4): 617-626.
[5] Ghabril M, Ma J, Patidar KR, et al. Eight-Fold Increase in Dietary Supplement-Related Liver Failure Leading to Transplant Waitlisting Over the Last Quarter Century in the United States. Liver Transpl,2022,28(2): 169-179.
[6] Hayashi PH, Rockey DC, Fontana RJ, et al. Death and liver transplantation within 2 years of onset of drug-induced liver injury. Hepatology,2017,66(4): 1275-1285.
[7] Arconzo M, Piccinin E, Moschetta A. Increased risk of acute liver failure by pain killer drugs in NAFLD: Focus on nuclear receptors and their coactivators. Dig Liver Dis,2021,53(1): 26-34.
[8] Tao J, Xue C, Wang X, et al. GAS1 Promotes Ferroptosis of Liver Cells in Acetaminophen-Induced Acute Liver Failure. Int J Med Sci,2023,20(12): 1616-1630.
[9] Xiang DD, Liu JT, Zhong ZB, et al. MicroRNA-29a-3p Prevents Drug-Induced Acute Liver Failure through Inflammation-Related Pyroptosis Inhibition. Curr Med Sci,2023,43(3): 456-468.
[10] Jiang SX, Hussaini T, Yoshida EM. N-acetylcysteine for non-acetaminophen induced acute liver failure: A review. Saudi J Gastroenterol,2022,28(2): 85-91.
[11] Lee WM, Hynan LS, Rossaro L, et al. Intravenous N-acetylcysteine improves transplant-free survival in early stage non-acetaminophen acute liver failure. Gastroenterology,2009,137(3): 856-864.
[12] Amjad W, Thuluvath P, Mansoor M, et al. N-acetylcysteine in non-acetaminophen-induced acute liver failure: a systematic review and meta-analysis of prospective studies. Prz Gastroenterol,2022,17(1): 9-16.
[13] Chen M, Suzuki A, Borlak J, et al. Drug-induced liver injury: Interactions between drug properties and host factors. J Hepatol,2015,63(2): 503-514.
[14] McPhail MJ, Farne H, Senvar N, et al. Ability of King's College Criteria and Model for End-Stage Liver Disease Scores to Predict Mortality of Patients With Acute Liver Failure: A Meta-analysis. Clin Gastroenterol Hepatol,2016,14(4): 516-525.
[15] Koch DG, Tillman H, Durkalski V, et al. Development of a Model to Predict Transplant-free Survival of Patients With Acute Liver Failure. Clin Gastroenterol Hepatol,2016,14(8): 1199-1206.
[16] Umbaugh DS, Nguyen NT, Curry SC, et al. The chemokine CXCL14 is a novel early prognostic biomarker for poor outcome in acetaminophen-induced acute liver failure. Hepatology,2023.
[17] Kwan R, Chen L, Park MJ, et al. The Role of Carbamoyl Phosphate Synthetase 1 as a Prognostic Biomarker in Patients With Acetaminophen-induced Acute Liver Failure. Clin Gastroenterol Hepatol,2023,21(12):3060-3069.e8.
[18] Rosen HR, Biggins SW, Niki T, et al. Association Between Plasma Level of Galectin-9 and Survival of Patients With Drug-Induced Acute Liver Failure. Clin Gastroenterol Hepatol,2016,14(4): 606-612 e3.
[19] Han L, Huang A, Chen J, et al. Clinical characteristics and prognosis of non-APAP drug-induced acute liver failure: a large multicenter cohort study. Hepatol Int,2023. |
